So many investment opportunities are worth noting! Click to view the 2025 investment outlook>>

Northeast Pharmaceutical Group's low P/E ratio is due to its three-year growth being lower than market forecast. Investors doubt the potential for earnings improvement justifies a higher P/E ratio. If medium-term earnings trends persist, a strong share price rise seems unlikely.